Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial

By sjmartinez • April 2, 2025

Bandos H, Kim S, Henry NL, Hays RD, Calsavara VF, Luu M, Gresham G, Lu KY, Irvin WJ, Suga JM, Siddique S, Cecchini RS, Rogatko A, Yothers G, Tighiouart M, Ganz PA. Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial. JNCI Cancer Spectr. 2025 Apr 1:pkaf032. doi: 10.1093/jncics/pkaf032. Epub ahead of print. PMID: 40170372.

Tags: Cedars Sinai DoM, General Internal Medicine, Hematology/Oncology, Publications

Related Posts

Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study

Freaney PM, Huang X, Petito LC, Grobman WA, Catov J, Hauspurg A, Bairey Merz CN, Bello N, Kim JK, Lane A, Haas DM, Levine LD,[...]

Effectiveness of mailed versus in-person PAP initiation in VA’s TeleSleep program

Gomez A, Sarmiento KF, Smith C, Mitchell M, Lee D, Totten A, Sanders E, Ryden AM, Seo J, Bhattacharyya S, Harris B, Mempin R, Moghtaderi[...]

Two-year Outcomes of Transcatheter Edge-to-edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Trial

Kar S, Makkar RR, Whisenant BK, Hamid N, Naik H, Tadros P, Price MJ, Singh G, Schwartz JG, Kapadia S, Alli O, Horr S, Seshiah[...]